The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid

Table 5 Short Term Disability 1 year after index date for OC/OP/SG cancer patients and their matched comparison group among commercial enrollees

VARIABLE	Patients with OC/OP/SG Cancer N = 281		Matched Comparison Group N = 281		Cost Burden^A
	COUNT/MEAN	%/STD DEV	COUNT/MEAN	%/STD DEV	Diff	P-value^B
Short-Term Disability (STD) Data
Patients with any STD	125	44.5%	23	8.2%	36.3%	<0.0001
Number of days of STD among all eligible patients^C	48.3	88.5	3.4	16.9	44.9	<0.0001
Number of days of STD among patients with any STD^D	108.7	105.3	42.0	44.0	66.6	<0.0001
Cost among all eligible patients^E	$7,952	$14,563	$566	$2,779	$7,386	<0.0001
Cost among patients with any STD^E	$17,876	$17,322	$6,916	$7,240	$10,960	<0.0001

For sample with 1 year of follow-up.
Notes
A. Cost burden is the difference between mean costs for O/P cancer patients and their matched comparison group.
B. P-value from test of the significance of the difference between patients with O/P cancer and their matched comparison group.
C: All eligible patients are those found in the STD database. Patients may have had 0 days of STD.
D: Patients with any STD are all patients with at least one STD day.
E: STD payments were imputed by an hourly rate of $29.37, value each STD day at 70% compensation (e.g., STD Payment = STD days* 0.7*29.37*8).